U.S. Subsidiary – EG BioMed US
EG BioMed US was established in Washington State, USA, in 2024, and is certified under the CLIA (Clinical Laboratory Improvement Amendments) regulations. It provides regulatory-compliant shared laboratory services for biotech companies aiming to enter the U.S. market, accelerating innovations in precision medicine, raising health awareness, and supporting businesses in expanding their global market presence.
Taiwan Subsidiary – EG Clinical Laboratory
EG Clinical Laboratory, founded in 2024, focuses on gene methylation technology to offer early blood cancer detection and is committed to precise health assessments. At the same time, it plans to provide health screening packages that meet public needs, helping individuals monitor their health status and prevent disease risks early.
